PeptideStack
5.2kquestions
20kanswers
220users

Would you accept 98.2% on a GLP-1 receptor agonist from QST without a content assay?

Asked 8 Apr 2025Modified 12 months agoViewed 11k times
7

What I am working with: 98.2% · a GLP-1 receptor agonist · QST.

I would like to set this up properly once, rather than adjust it repeatedly.

My budget is real but not tight, and my tolerance for uncertainty is low.

What would you do, and what would make you change course?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

438 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

436 questions
shareeditfollowflag
BN
askedbridget_nyathi16k178 Apr 2025

5 Answers

Accepted answer first, then by votes
99

Accepted answer

More usefully, understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

Concretely, column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
SC
answered · acceptedstopper_core50k13820 Jun 2025
2Thank you — the worked example is what makes this usable. – rhian_prydderch 7 months ago
Related: the same reasoning applies to the counter-ion question. – hana_petrikova 5 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
38

Worth being precise here: start from what the detector sees, because that tells you what the number means.

Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

edited 27 Jul 2025 by juliette_farnese — removed a claim I could not source

shareimprove this answerflag
JF
answeredjuliette_farnese12k281 Jul 2025
4Related: the same reasoning applies to the counter-ion question. – aine_mulcahy 10 months ago
add a comment
31

To be exact about it, the short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
DA
answeredDr_Yusuf_Adeyemi95k24812 Jul 2025
5This is the first explanation of that which has actually made sense to me. – Dr_Yusuf_Adeyemi 7 months ago
4Note that the label instructions differ between agents on precisely this point. – bufferline42 5 months ago
add a comment
24

Specifically, purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
LD
answeredloss_on_drying47k13823 Jul 2025
18

Stated carefully, the single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
TR
answeredtobias_reint19k273 Aug 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.